Premium
Plateletpheresis with the IBM Model 2997
Author(s) -
Mishler John Milton,
Lund Patricia,
Borberg Helmut
Publication year - 1980
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1980.tb02328.x
Subject(s) - plateletpheresis , hypocalcaemia , medicine , calcium , chemistry , anesthesia , surgery , platelet , apheresis
. 9 healthy subjects dosed with acid‐citrate‐dextrose, NIH formula B (ACD‐B) while undergoing plateletpheresis with the continuous‐flow IBM Model 2997 centrifuge, received on average 59.5 ± (SD) 3.2 mg Na 3 citrate‐kg ‐1 . h ‐1 . This rate of infusion of Na 3 citrate resulted in a maximum 12‐fold rise in the concentration of citrate in serum (plasma) following the processing of 10 litres of whole blood, and subsequently reduced the level of total calcium in serum (plasma) by 9%. This dose of Na 3 citrate produced no clinical symptoms suggestive of hypocalcaemia in these subjects, even though the use of acid‐citrate‐dextrose, NIH formula A (ACD‐A) under identical conditions has been reported to reduce significantly the level of total calcium in serum, and concomitantly increase the number or reactions occurring in donors. From previous studies employing the intermittent‐flow centrifugation system of plateletpheresis, a rate of infusion of Na 3 citrate below 65 mg.kg ‐1 . h ‐1 can insure maximum donor safety and this rate can be achieved with the IBM Model 2997 by the utilisation of ACD‐B.